C linical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE), a randomized trial in which a total of 2287 patients were enrolled and followed for a median of 4.6 years, compared percutaneous coronary intervention (PCI) plus intensive pharmacological and lifestyle intervention (optimal medical therapy [OMT]) to OMT alone in reducing the risk of cardiovascular events in patients with stable coronary artery disease (CAD). Similar to other clinical trials, among patients with stable CAD, PCI exhibited no significant effect in reducing the risk of death, myocardial infarction, or other major cardiovascular events. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] On the other hand, PCI with OMT was demonstrated to temporarily improve angina control compared with OMT alone. 11 Because health status, specifically that related to angina, is a primary therapeutic goal in treating patients with stable CAD, it is a meaningful measure of outcome for cost-effectiveness analysis. In this analysis, we examined the relative costs and cost-effectiveness of treating angina with respect to the severity of angina at the time of presentation. The results in this analysis provide a framework for comprehending the economic impact of PCI and medical strategies targeted at reducing angina.
WHAT IS KNOWN
• Among patients with stable coronary artery disease, percutaneous coronary intervention (PCI) exhibited no significant effect in reducing the risk of death, myocardial infarction, or other major cardiovascular events. • Adding PCI to optimal medical therapy (OMT) was not proven a cost-effective initial management strategy for symptomatic chronic coronary artery disease.
WHAT THE STUDY ADDS
• The Seattle Angina Questionnaire health status instrument could be a critical method for evaluating the costs of attaining a clinically important outcome and meaningful measure of outcome for costeffectiveness analysis. • For the patients with worse baseline scores of the Seattle Angina Questionnaire in each domain, adding PCI to OMT improved angina-related health status but at a cost that is likely prohibitive as a routine initial management strategy. • The incremental cost of PCI to provide meaningful clinical benefit above that achieved by OMT alone was lower for patients with severe angina than for those with mild or no angina.
Methods

Trial Summary
The study design and methods used in COURAGE trial have been previously described in detail. [7] [8] [9] [10] [11] Between 1999 and 2004, 2287 of 3071 eligible patients were randomized at 50 US and Canadian centers to PCI plus OMT (1149 patients) or OMT alone (1138 patients). Follow-up was for a median 4.6 years (range, 2.5 to 7.0 years). After local institutional review board approval, each patient signed informed consent to participate in the trial. Entry criteria included stable CAD, stenosis of Ͼ70% in at least 1 major epicardial coronary artery with objective evidence of myocardial ischemia, or at least 1 coronary stenosis of Ͼ80% in those with typical angina symptoms. Patients with persistent Canadian Cardiovascular Society (CCS) class IV angina, refractory heart failure, cardiogenic shock, revascularization within the previous 6 months, or coronary anatomy unsuitable for PCI were excluded. 12 The primary and secondary end points have been described previously. 7
Assessment of Severity of Angina
The impact of angina on health status was the focus of the quality-of-life assessment, which was a secondary end point in COURAGE. 9 -11 At baseline, the Seattle Angina Questionnaire (SAQ) and CCS classification were used to assess the severity of angina. 11 The SAQ was completed at 1, 3, 6, and 12 months and then annually thereafter until the end of the trial. The SAQ is a coronary disease-specific quality-of-life measure comprising 19 items that quantify 5 clinically relevant domains of health status. The physical limitation domain assesses how daily activities, such as dressing, walking, or strenuous activities, were restricted due to angina. The angina stability domain measures 1-month change in the severity of angina. The angina frequency domain quantifies the frequency of angina over the preceding month. The treatment satisfaction domain characterizes overall satisfaction with the current treatment of angina, and the quality-of-life domain describes the patient's assessment of the impact of angina on his or her quality of life. Scores in each domain range from 0 to 100, with higher scores indicating better health status.
Three domains of the SAQ-physical limitation, angina frequency, and quality of life-were stratified into tertiles based on scores at randomization. The angina stability and treatment satisfaction domains were excluded because they overlap somewhat with the other domains. The lowest tertile represents the most severe angina, physical limitation, or impaired disease-specific quality of life, whereas the highest reflects the best level of health and functioning.
On the basis of criteria suggested by Wyrwich et al, 13 clinically significant intraindividual change in the physical limitation, angina frequency, and quality-of-life domains were increases in scores of Ն8, Ն20, and Ն16, respectively. Clinically significant change can be defined as the smallest difference in a score in a domain of interest that patients perceive as beneficial and that would warrant a change in the patient's management. In each SAQ domain, 5 response-state options were recommended to reflect the clinically significant change. For example, in the angina frequency domain, there are 2 items (frequency of symptoms and use of tablets) with 6 responsestate options for each item (4 or more times per day, 1 to 3 times per day, 3 or more times per week but not every day, 1 to 2 times per week, less than once a week, none over the past 4 weeks). A state change is the smallest amount that an individual's score can shift by moving up or down 1 response choice on 1 item on the scale while all other responses remain the same. The magnitude of a state change equals 20 points on the 0 to 100 total scale score range per scale item range in angina frequency. The state change, such as from "some of the time" to "a little of the time," is considered a clinically significant change in the domain of angina frequency.
Absolute net benefit; number of patients needed to treat for 1 patient to achieve clinically significant relief from angina, function, or quality-of-life improvement; and the cost of improvement in angina-related health status were estimated. In each of the 3 domains, cost and cost-effectiveness were analyzed on the basis of significant interactions between treatment group and baseline score.
Assessment of Cost
The cost-effectiveness analysis of PCI with OMT versus OMT alone using life years or quality-adjusted life years as an effectiveness measure has been published previously. 14 The primary purpose of the current cost-effectiveness analysis was to use relief from angina as an effectiveness measure and to perform an incremental costeffectiveness analysis by tertiles of baseline score in the 3 domains of physical functioning, angina frequency, and quality of life.
As previously described in the cost-effectiveness analysis in COURAGE, 14 the estimation of costs was based on direct medical care costs, including hospitalizations, medications, and outpatient care. After the first year, costs beyond the trial period were discounted 3% annually. We used 2004 US dollars for all costs, with resource use and clinical outcomes from all 2287 patients across 3 healthcare systems (US Veterans Affairs, US non-Veterans Affairs, and Canada).
Medical care costs were estimated on the basis of cardiovascular healthcare resource use associated with the index and all follow-up hospitalizations. [15] [16] [17] [18] In this analysis, resource utilization included (1) inpatient or outpatient initial PCI, index hospitalization, or outpatient care other than PCI; (2) subsequent hospitalizations, including subsequent PCI; (3) medications, including cost of clopidogrel after PCI; (4) outpatient visits; and (5) cardiovascular tests during follow-up. A diagnosis-related group code was assigned for each initial and subsequent hospitalization, as used in the US Medicare program. Costs for each diagnosis-related group were estimated using average Medicare reimbursement rates obtained from the Medicare Part A data file. 19 Outpatient procedures, including PCI, physician office visits, tests, and emergency department visits, were coded by Current Procedural Terminology codes and assigned a cost based on the Medicare fee schedule. 14
Statistical Analysis
The intention-to-treat principle was applied to all analyses. Patients were grouped into tertiles for physical limitation, angina frequency, and quality of life on the basis of the distribution within each domain. The unpaired Student t test was used to compare continuous variables. The 2 test or the Wilcoxon rank sum test was used to compare categorical variables, including assessing freedom from angina and proportions with clinically significant increases from baseline. Bootstrap methods (5000 replicates) were used to estimate variability of cost and relief from angina. 20 Incremental costeffectiveness ratios (ICERs) were calculated for 1 additional patient to have clinically significant improvement in physical functioning, angina frequency, and quality of life.
To address the uncertainty of the effect of cardiovascular healthcare resource use on cost and improvement in angina, [21] [22] [23] probabilistic sensitivity analysis was conducted to assess the impact of all sources of uncertainty involved in the calculation of cost and benefits. The probability assumptions of cost have been described previously. 14 Monte Carlo simulation was performed to derive the differences in mean cost between the PCI and the OMT groups. S-plus version 7.0 (Insightful Corp, Seattle, WA) and SAS version 9.1 (SAS Institute, Cary, NC) software were used for all statistical analyses.
Results
Baseline Characteristics and End Points According to Tertiles of Baseline Score
The tertile cut points for the physical limitation domain were Ͻ53, 53 to 81, Ͼ81; for angina frequency, Ͻ50, 50 to 80, Ͼ80; and for quality of life, Ͻ42, 42 to 59, Ͼ59. Table 1 shows the frequency of baseline characteristics and end points between the PCI plus OMT and the OMT groups according to tertiles of baseline scores, along with the distribution of patients, for the physical limitation domain (online-only Data Supplement Tables 1 and 2 for angina frequency and quality of life, respectively). Overall, there was little or no difference in baseline characteristics between treatment groups within any domain, except for a slightly older age in the PCI group within the second tertile of angina frequency (Pϭ0.02). Across tertiles, there was no significant difference in age for the physical limitation domain. However, the percentage of male patients increased with higher tertiles (better function) in the physical limitation domain (from 82.2% to 87.4% to 88.6%; Pϭ0.0002). The prevalence of prior myocardial infarction significantly decreased from 44.0% to 35.9% to 38.0% (Pϭ0.01) as the baseline score in physical limitation changed from the lowest to highest tertile. Diabetes, hypertension, and median duration of angina showed similar trends. Similar results were observed across tertiles of the angina frequency and quality-of-life domains.
There were no significant differences in the primary end points between the 2 treatment groups within all 3 domains across tertiles. The results of mean observed scores with SD and proportion of patients who had a clinically significant improvement on the SAQ for 3 tertiles in 3 domains were published previously. 11 On the other hand, the event rates of the primary and secondary outcomes significantly correlated with the severity of angina. As the scores in the domain of physical limitation varied from the lowest third through the middle to the highest third, the event rates of the primary outcome (death or myocardial infarction) decreased from 26.1% to 16.5% to 12.3% (PϽ0.0001), whereas death fell from 11.6% to 6.2% to 3.8% (PϽ0.0001); similar findings were noted for myocardial infarction and stroke and for the composite of death, nonfatal myocardial infarction, and stroke, decreasing from 28.3% to 17.0% to 12.9% (PϽ0.0001). Similar results were observed in the domains of angina frequency and quality of life (online-only Data Supplement Tables 1 and 2 ).
Benefits for Improvement of Angina-Related Health Status at 6 Months and Total In-Trial Cost According to the Tertile of Baseline Score
Adding PCI to OMT had clinically significant incremental benefits in angina severity from 1 to 6 months in the lowest and middle tertiles of each domain. However, beyond 6 months postrandomization, there were no significant differences between PCI with OMT and OMT alone with respect to clinically significant improvements in angina severity in the lowest and highest tertiles of the 3 domains. Corresponding differences ranged from 0% to 4%. 11 Table 2 shows data for the 3 major SAQ domains by severity of angina-related health status at 6 months. The fraction with a clinically significant benefit with respect to angina by treatment group, the benefit of PCI plus OMT compared to OMT alone, as well as the total in-trial costs are shown. Compared with the OMT group, the PCI group had the largest clinically significant improvement in angina for the lowest tertile in physical limitation (11.82%, Pϭ0.006) and quality of life (10.16%, Pϭ0.003) and for the middle tertile in angina frequency (8.15%, Pϭ0.02). The PCI group did not show significant clinical improvement compared with OMT alone for the highest tertile for any domain. The number of patients needed to treat ranged from 10 to 40 for patients with the lowest and middle tertile baseline scores, and from 51 to 500 for patients with the highest tertile baseline scores.
Of interest, for both the PCI plus OMT and the OMT-alone groups, costs were higher in patients with more severe angina. For instance, for the PCI plus OMT group, the lowest tertile of angina frequency cost was $42 600; the middle tertile, $35 013; and the highest tertile, $30 121.
For each tertile among all 3 domains, costs were significantly higher for the PCI group. For the lowest tertile in the physical limitation domain, the average total in-trial cost for the PCI group was $9392 higher ($43 232 versus $33 840; 95% CI of the difference, $4310 to $14 808). Similar results were observed in the middle and highest tertiles between the 2 treatment groups.
The difference in total in-trial cost between the treatment groups was mainly due to the difference in initial cost caused by the expense of the PCI procedure (about $10 000). Overall, the interaction between cost difference and tertiles was not significant. For the physical limitation domain, the differences ranged from $9392 to $8691 to $10 419, as SAQ scores varied from lowest to middle to highest. However, the trends were different in the domains of angina frequency and quality of life (Table 2) . From 6 months to 3 years, estimated on the same time frame, the cost difference between treatment groups remained stable (from $9770 to $13 100) in each tertile of all domains (online-only Data Supplement Tables 3 through 6 ). The difference in each time frame and total in-trial cost between the treatment groups was mainly due to the difference in initial cost, which was about $11 000 higher in the PCI group. Thus, the initial difference in cost between treatment groups due to the PCI procedure carried forward and was never recovered. Table 3 shows the cost-effectiveness analysis for in-trial improvement of angina-related health status according to the tertile of baseline score. Compared with the OMT group, the point estimate of the in-trial ICER for PCI was $79 448 per patient with significant clinical improvement in physical limitation among those with the lowest tertile baseline score; Ͼ99% of all estimates were in the upper-right quadrant of the cost-effectiveness plane, representing a high probability that PCI provides greater benefit with additional cost ( Figure 1A) . A cost-effectiveness acceptability curve indicates that the bootstrap-derived cost-effectiveness estimates were 20.0% for Ͻ$50 000 and 66.9% for Ͻ$100 000 per patient with significant clinical improvement ( Figure 1B) .
Cost-Effectiveness Analysis: Improvement of Angina-Related Health Status at 6 Months According to the Tertile of Baseline Score
For patients with the lowest tertile baseline score of angina frequency, both the PCI plus OMT and OMT-alone groups had large clinically significant improvements in angina (201/ 236 [85%] versus 159/196 [81%], respectively). It is likely that more subsequent procedures (crossover) in the lowest For patients with the lowest tertile of quality-of-life domain, the ICER of PCI compared with OMT was $113 962 per patient with significant clinical improvement, with 2% of observations Ͻ$50 000 per-patient significant clinical improvement and 38% of observations Ͻ$100 000 per patient. The ICERs for the highest tertiles were considerably higher than the first and second tertiles. Thus, for the physical limitation domain, the ICER was $79 448 in the lowest tertile, $99 614 in the middle tertile (Figure 2A and  2B) , and $526 560 in the highest tertile ( Figure 3A and 3B). Similar patterns were observed for angina frequency and quality of life.
Approximately 22% of the patients were free of angina at baseline, and for these patients, PCI should not provide any added health benefit. To examine the economic impact of freedom from angina and related cost-effectiveness, we classified baseline angina frequency in an alternative way 24, 25 : angina free (score, 100), monthly (score, 61 to 99), weekly (score, 31 to 60), and daily (score, 0 to 30). Onlineonly Data Supplement Table 7 and online-only Data Supplement Appendix A show the results of the cost and costeffectiveness analysis. It is worth noting that adding PCI to OMT did not result in greater freedom from angina for the patients with the highest tertiles of angina frequency baseline score, but it did offer significant benefit for patients with the lowest and middle tertiles of angina frequency baseline score for a 6-to 12-month period.
Beyond 6 months, there were no significant differences in effectiveness between the 2 groups in lowest and highest tertiles of each domain. Specifically, incremental effectiveness ranged from 0 to no more than 4%. For the highest tertiles in each domain, there were no statistically significant differences in clinical improvement between the 2 treatment groups during the follow-up period. For the lowest and middle tertiles of the physical limitation and quality-of-life domains, additional benefits appeared for up to 6 months and disappeared beyond 6 months; for the lowest tertile in angina frequency, additional benefits disappeared beyond 3 months. Only in the middle tertile of angina frequency were there significant advantages of PCI with respect to the percentage of patients with clinically significant improvements at 1 year (67% versus 58%; Pϭ0.04) and 2 years (71% versus 59%; Pϭ0.007). As a result, beyond 6 months in each tertile of the physical limitation and quality-of-life domains, the ICERs rapidly increased from 6 months to 3 years Ͼ$300 000 per additional patient with clinically significant improvement and even dominated by the OMT at 2 or 3 years ( Figure 4A and 4B, online-only Data Supplement Tables 3 through 6 , onlineonly Data Supplement Appendix B).
Sensitivity Analysis for In-Trial ICERs
The estimates of ICERs are related to uncertainties of variables involved in total in-trial cost and percentage of patients having significant clinical improvement. The characteristics of variables used in the probabilistic sensitivity analysis have been described previously. 14 The contour plots of simulated distribution of mean differences in costs and benefits in significant clinical improvement based on the probabilistic sensitivity analysis for the lowest tertile baseline score in the physical limitation domain are shown in Figure  5A . The ellipses indicate 50%, 95%, and 99% CIs of the simulated in-trial ICERs. Figure 5A reveals that the percent-age of patients with significant incremental clinical improvement could range from 3% to 18% for the PCI group compared to the OMT group (from 1% to 5%), and the cost for the PCI group would be $4100 to $14 000 higher, indicating a strategy of clinical benefit with greater cost.
The cost-effectiveness acceptability curve ( Figure 5B ) shows that the variation in this sensitivity analysis was greater than noted purely by the play of chance. There was about 60% to 85% probability of PCI being cost-effective at the $50 000 and $100 000 thresholds, respectively, with posterior probability of 0.90 that PCI was more effective. For the lowest tertile baseline score in angina frequency and quality of life, there was about 5% and 14% and 24% and 46% probabilities of PCI being cost-effective at the $50 000 and $100 000 thresholds, respectively.
Similar results were observed for patients with the middle tertile in the angina frequency domain and lowest and middle tertiles in the quality-of-life domain. For patients in the highest tertile at baseline in each domain, results on the basis of probabilistic sensitivity analysis did not show the posterior probability that adding PCI to OMT could be a cost-effective strategy.
Discussion
The results indicate that for the patients with worse baseline scores of the SAQ in each domain, adding PCI to OMT improved angina-related health status, but at a cost that is likely prohibitive as a routine initial management strategy. These results show that PCI is more cost-effective as a treatment for angina in patients with severe angina than in those with mild or no angina at baseline. However, because the cost for 1 patient to have clinically significant improvement in each tertile within any domain would be much Ͼ$50 000, it is uncertain that there is any level of severity of angina for which an initial strategy of PCI would meet a societal willingness-to-pay threshold. The SAQ results at 6 months were used for the primary analysis because this offered the most consistent treatment effect of PCI and thus would offer the most optimistic (ie, lowest) ICERs. However, the findings should not be interpreted as reflecting results only at 6 months but, rather, the overall most-optimistic view of cost-effectiveness of PCI as a treatment for angina.
It is difficult to evaluate the added cost of PCI for improvement in angina in cost-effectiveness analysis. 26 -28 More than $250 000 for 1 patient to derive a clinically significant improvement in any anginal symptoms with PCI would not likely meet a societal willingness-to-pay threshold. Nonetheless, categorizing the severity of angina on the baseline score of SAQ may be helpful in deciding whether a patient with stable coronary disease should have PCI in addition to OMT. The results from this study further question the efficacy of adding PCI to OMT as an initial treatment strategy among the patients with stable coronary disease. The COURAGE trial revealed that adding PCI to OMT did not prolong survival, suggesting that the best advantage from PCI with OMT was reducing the burden of angina. The issue is: What would society be willing to pay for a patient to become angina free from 6 months to several years after PCI?
Few studies on the economic impact of angina in patients with coronary disease have been conducted. Arnold et al 25 evaluated the relationship between angina frequency from the SAQ and resource utilization and found that compared with patients who were angina free (score of 100 in angina frequency), patients with scores 0 to 30 in angina frequency had at least double the cost in resource utilization. The findings in of the present study exhibited similar results; for example, for both the PCI plus OMT and the OMTalone groups, costs were higher in patients with more severe angina. However, only the economic impact of angina frequency was analyzed in the study of Arnold et al, and no other domains of quality of life, such as physical limitation, were investigated. Furthermore, costeffectiveness analyses on the basis of clinically significant improvement in clinical trials of coronary disease have not been conducted.
CCS classification is another instrument to assess the severity of angina but was not examined. CCS class 0 could be defined as angina free, meaning neither causing nor exhibiting symptoms of angina. The percentage without angina on the basis of CCS class was 12.4% (12% in the PCI plus OMT group and 13% in the OMT-only group). The percentage without angina on the basis of the SAQ (with angina frequencyϭ100) was 22%; the percentages with perfect physical limitation and quality of life (scoreϭ100) were 11% and 4.4%, respectively.
There are several limitations to this study. Missing data are a key issue for a clinical trial with a long follow-up period, especially for quality-of-life data. During the follow-up through 6 months, the percentages of missing data were Ϸ20% in each domain. Multiple partial imputation strategies were used to evaluate the impact of missing data. Imputed data sets were generated for analysis, and the results of each were combined to estimate regression parameters. These data were then analyzed by a pattern-mixture model. 29, 30 Although potential bias from missing data cannot be definitively excluded, analyses to account for missing data did not identify meaningful bias.
There also were crossovers from OMT to revascularization. For the physical limitation, angina frequency, and quality-of-life domains in lowest tertile, the rates of crossover were 13.18%, 11.34%, and 12.04%, respectively; in the middle tertile, the rates were 9.23%, 11.95%, and 10.72%, respectively; and in highest tertile, the rates were 5.45%, 5.18%, and 5.62%, respectively. Even though a higher frequency of crossovers among patients with lower SAQ scores was observed, the cost differences between the 2 treatment groups were not always less with lower SAQ scores.
Few drug-eluting stents were used in the study, and ranolazine was not available. Of note, this strategy trial was evaluated by intention to treat, and thus, these results should be interpreted as a study of the cost-effectiveness of an initial strategy of PCI versus no PCI.
Conclusions
Baseline SAQ scores are an important determinant of the cost-effectiveness of PCI as an initial strategy for stable angina. The incremental cost of PCI to provide meaningful clinical benefit above that achieved by OMT alone was lower for patients with severe angina than for those with mild or no angina. However, it is uncertain that at any level of angina severity that PCI as an initial strategy would achieve a socially acceptable cost threshold.
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